FDA has approved BeiGene’s PD-1 inhibitor for gastric or gastroesophageal junction adenocarcinoma
BeiGene shared a post on LinkedIn:
“News for Investors and Media: Today we announced the U.S. FDA has approved our PD-1 inhibitor, in combination with chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (≥1).
Gastric cancer is the world’s 5th most common cancer, and in the U.S. approximately 27,000 patients are diagnosed each year. This approval marks a significant step forward in our mission to deliver transformative therapies to patients with cancer.”
Proceed to the video attached to the post.
Read the post “TEVIMBRA Received FDA Approval as First-Line Therapy for Gastric and GEJ Cancers in Combination with Chemotherapy” on oncodaily.com.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023